Tissue Regenix Group (FRA:LSW) Total Payout Ratio: 0.00 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LSW Tissue Regenix Group PLC FRA:LSW
10 GF Score
Price €0.07
GF Value €0.84
! 5 Warning Signs
View Full Analysis

What is Tissue Regenix Group Total Payout Ratio?

Tissue Regenix Group FRA:LSW 10 Total Payout Ratio is 0.00 as of Jul. 18, 2026. GuruFocus rates FRA:LSW with a GF Score™ of 10/100 and a GF Value™ of €0.84. The stock has 5 warning signs investors should review.

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Tissue Regenix Group's current Total Payout Ratio is 0.00.

Tissue Regenix Group Total Payout Ratio Related Terms

Tissue Regenix Group Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Tissue Regenix Group's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tissue Regenix Group Total Payout Ratio Chart

Tissue Regenix Group Annual Data
Trend Jan15 Jan16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.42 0.00 0.00 0.04 0.27

Tissue Regenix Group Semi-Annual Data
Jul15 Jan16 Jul16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.78 0.00 0.00

FRA:LSW vs VRTX, REGN, ALNY: Total Payout Ratio Comparison

For the Biotechnology subindustry, Tissue Regenix Group's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tissue Regenix Group Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Tissue Regenix Group's Total Payout Ratio falls into.


FRA:LSW
10GF Score
Tissue Regenix Group PLC FRA:LSW
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tissue Regenix Group Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Tissue Regenix Group's Total Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0.099 + 0) / -0.374
=0.26

Tissue Regenix Group's Total Payout Ratio for the quarter that ended in Jun. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -0.843
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Ratio →
What does a Total Payout Ratio of 0.00 mean?
Tissue Regenix Group (FRA:LSW) has a Total Payout Ratio of 0.00 as of Jul. 18, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Tissue Regenix Group and its competitors.
Is Tissue Regenix Group's Total Payout Ratio too high?
Tissue Regenix Group's current Total Payout Ratio is 0.00. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's Total Payout Ratio compare to VRTX and REGN?
Tissue Regenix Group's Total Payout Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Tissue Regenix Group and its competitors. Tissue Regenix Group's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current Total Payout Ratio of 0.00. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current Total Payout Ratio is 0.00. Tissue Regenix Group's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current Total Payout Ratio is 0.00 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?

Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued. The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.

Key valuation signals for FRA:LSW:

  • Total Payout Ratio: 0.00
  • GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
  • GF Score™: 10/100 with 5 warning signs

No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tissue Regenix Group Business Description

Address Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score

Get the complete analysis for FRA:LSW

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.84
GF Value